Showing 21-30 of 1743 results for "".
Botox for Chronic Migraine: Tips and Tricks
https://practicalneurology.com/diseases-diagnoses/headache-pain/botox-for-chronic-migraine-tips-and-tricks/30277/Ten Questions for Andrew M. Blumenfeld, MDMonoclonal Antibody Studies
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/monoclonal-antibody-studies/30233/An Interview with Rachelle S. Doody, MD, PhDAdult-Onset Cerebellar Ataxias
https://practicalneurology.com/diseases-diagnoses/movement-disorders/adult-onset-cerebellar-ataxias/31221/Pravin Khemani, MD, Medical Director, Movement Disorders Program, Swedish Neuroscience Institute, provides a framework for evaluation of adult-onset cerebellar ataxias.ELEVATE (Qulipta for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments; NCT04740827)
https://practicalneurology.com/programs/practical-neurology/elevate-qulipta-for-prophylaxis-of-migraine-in-participants-who-failed-previous-oral-prophylactic-treatments-nct04740827/31255/Patricia Pozo-Rosich, MD, PhD, Headache Specialist from the Vall d’Hebron University Hospital in Barcelona, Spain, provides an overview of the ELEVATE clinical trial.A Mark of Success?
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/a-mark-of-success/31075/Achim Schneeberger, MD, talks about the Phase II study that demonstrated clinical and biomarker effects consistent with disease modification in Alzheimer's. (headphones recommended)Advances in the Evaluation of TBI
https://practicalneurology.com/diseases-diagnoses/tbi/advances-in-the-evaluation-of-tbi/30093/Welcome to Neurology: Disease Deep Dive. In this episode, Dr. Beth McQuiston, MD, RD, Medical Director at Abbott Laboratories, and Dr. David Okonkwo, MD, PhD, Professor of Neurological Surgery, Clinical Director of the Brain Trauma Research Center, and Director of the Neurotrauma Program at UniversiSeeking Breakthroughs: The Industry Perspective
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/the-industry-perspective/30192/A roundtable discussion with Gregory Went, PhD, Adamas Pharmaceuticals; Lynn Kramer, MD, Eisai; Paulo Fontoura, MD, PhD, Genentech/Roche; Justin Gover, BSc, MBA, GW Pharmaceuticals; Marc Kamin, MD, SK Life Sciences; and Mike Davis, BSc, MBA, UCBNovember/December 2015 Case Challenge: A 70-Year-Old Man with a Sudden Lisp
https://practicalneurology.com/diseases-diagnoses/neuromuscular/novemberdecember-2015-case-challenge-a-70-year-o/31086/By Mohanad Alzubaidi, MD and Aziz Shaibani, MD, FACP, FAAN, FANA A 70-year-old man presented with a six-month history of a "lisp," noted by his friends, that got worse the more he spoke. There was no diplopia, ptosis, dysphagia, muscle wasting, or extremities weakness. Since he was stresse- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31295/Management of Acute Seizures and Long-Term Antiepileptic Therapy: A Case StudyIn a recent article by Niranjan Siva, MD, and Amit Verma, MD, published in *Practical Neurology*, a 24-year-old male experienced two first-time generalized tonic-clonic seizures without aura within a two-hour period. Initi
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
https://practicalneurology.com/programs/practical-neurology/trials-in-2/35433/Christopher Moertel, MD, Medical Director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota provides an overview of the ReNeu clinical trial which evaluated the safety, effectiveness, and tolerability of Gomekli in children aged ≥2 years and adults.